Results 51 to 60 of about 143,676 (242)
Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]
, 2013 We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Abruscato, Mario Giovanni Rosario +3 more
core +2 more sources
Advanced Science, 2019 Although near‐infrared (NIR)‐light‐mediated photothermal thrombolysis has been investigated to overcome the bleeding risk of clinical clot‐busting agents, the secondary embolism of post‐phototherapy fragments (>10 µm) for small vessels should not be ...
Fengrong Zhang +6 more
doaj +1 more source
Clinical outcomes of submassive pulmonary embolism thrombolysis—an Indian experience
The Egyptian Heart Journal, 2020 Background Acute pulmonary thromboembolism is the most dangerous presentation of venous thromboembolic disease. The role of thrombolysis in massive pulmonary embolism has been studied extensively, but the same is not there for submassive pulmonary ...
Nadeem U. Rehman +3 more
doaj +1 more source
Thrombolysis and thrombectomy for acute ischaemic stroke [PDF]
, 2017 The likelihood of disability-free recovery after acute ischemic stroke is significantly improved by reperfusion either by intravenous thrombolytic drug treatment or with endovascular mechanical thrombectomy in selected cases.
El Tawil, Salwa, Muir, Keith W.
core +1 more source
Professional guideline versus product label selection for treatment with IV thrombolysis: an analysis from SITS registry [PDF]
, 2017 Introduction: Thrombolysis usage in ischaemic stroke varies across sites. Divergent advice from professional guidelines and product labels may contribute. Patients and methods: We analysed SITS-International registry patients enrolled January 2010
Alan C Cameron +8 more
core +1 more source
Health Technology Assessment in Action, 2017 Context: Application of anti-clot drugs such as recombinant tissue plasminogen activator (rt-PA) to treat patients with strokes is considered as a standard treatment employed through two techniques: intra-arterial and intravenous thrombolysis.
Mojtaba Nouhi +4 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2022 Background Many cardiac arrest cases are encountered annually worldwide, with poor survival. The use of systemic thrombolysis during cardiopulmonary resuscitation for the treatment of cardiac arrest remains controversial.
Omar A. Alshaya +5 more
doaj +1 more source
Thrombolysis for Cerebral Ischemia [PDF]
Frontiers in Neurology, 2010 The care for patients with acute ischemic stroke has been revolutionized by the clinical application of fibrinolysis. Intravenous recombinant tissue plasminogen activator (rt-PA) has been proven to improve functional outcomes following acute ischemic stroke and can be administered to a select group of patients up to 4.5 h after symptom onset. Time from
Elias A. Giraldo +2 more
openaire +4 more sources
Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis [PDF]
, 2007 Objective: To assess the cost effectiveness of primary angioplasty, compared with medical management with thrombolytic drugs, to achieve reperfusion after acute myocardial infarction ( AMI) from the perspective of the UK NHS.
Abrams, Keith +6 more
core +2 more sources
Stroke patients admitted within normal working hours are more likely to achieve process standards and to have better outcomes [PDF]
, 2015 Acknowledgements The authors are grateful to David Murphy of the SSCA for providing data and to Lynsey Waugh of ISD Scotland for linking the SSCA data with General Register Office data.
Barber, Mark +6 more
core +2 more sources